JAK2 and acquired polycythemia vera: Key factors influencing the development of thrombosis, in addition to age >60 years in patients with PV, include hematocrit >45%, elevated leukocyte count, concomitant cardiovascular risk factors, and the presence of the JAK2 V617F mutation.